Researchers Add More Screenings and Treatments Older Adults Should Stop Considering

The burden of screening does not fade with age, but the benefit often does

As the number of Americans age 65 and older climbs from 46 million to more than 98 million by 2060, the question of when to stop screening matters more every year. The problem is not just that some tests no longer help older adults enough to justify the risk. It is that the medical system still defaults to doing them, even when the better choice is to pause and rethink.

That shift is increasingly visible in cancer care. Major groups now lean toward individualized decisions instead of rigid age cutoffs, because age alone tells you too little about whether a test will help. Health status, function, life expectancy, and personal goals matter far more than a birthday on the calendar.

Which screenings are increasingly seen as low-value

The clearest examples are familiar ones. The U.S. Preventive Services Task Force recommends breast cancer screening until age 74. For prostate cancer, men ages 55 to 69 are supposed to discuss PSA screening with a clinician, while routine PSA screening is not recommended for men 70 and older. For colorectal cancer, both the task force and the American Cancer Society recommend screening until 75, then using individualized decisions from 76 to 85.

Cervical cancer screening is another place where stopping is usually the right move. Most guidelines recommend ending routine cervical screening at 65 for adequately screened, average-risk patients. That cutoff reflects a simple reality: once the risk of developing a cancer that screening can meaningfully prevent falls, the harms of false alarms, follow-up tests, and procedures begin to outweigh the upside.

The American Academy of Family Physicians has also highlighted a broader trend in older-adult care: screening guidance is moving away from strict age thresholds and toward patient-specific decision-making. That approach is especially important because older adults are not a single risk category. A healthy 68-year-old and a frail 84-year-old should not be treated as if they face the same trade-offs.

Why the evidence gets thinner after 75

The case for restraint gets stronger because the evidence base gets weaker with age. Most randomized screening trials did not include adults older than 75, which means the data supporting continued screening in later life are limited. When evidence is thin, the chance of benefit becomes harder to prove, while the chance of harm becomes easier to see.

That matters because screening is not a harmless act. It can lead to more biopsies, more repeat imaging, more follow-up visits, more anxiety, and sometimes treatment for cancers that would never have caused trouble during a patient’s remaining years. In older adults, that cascade can consume time and energy that might be better spent on mobility, heart health, pain control, or simply staying independent.

This is why the question should not be, “Can this test find cancer?” It should be, “Would finding it now change what happens in a way that improves this patient’s life?” In many older adults, especially those with limited life expectancy or significant health problems, the answer is no.

Patients often resist stopping, and doctors often do not bring it up

The hardest part of reducing low-value screening is that many older adults do not want to stop, and many clinicians never start the conversation. A University of Michigan study found that nearly 40% of adults considered stopping colon cancer screening at 75 unacceptable. In a 2023 National Poll on Healthy Aging, 62% of adults ages 50 to 80 disagreed with using life expectancy to decide when to stop cancer screening.

That hesitation shows up in real-world care. A Medicare survey study found that cancer screening remained common even among older adults unlikely to benefit. Among women 76 and older, 53% had mammography in the past year or intended to keep screening. Among men 71 and older, 61% had PSA screening in the past year or intended to continue.

What stands out most is how rarely doctors appear to initiate stopping discussions. In that study, only 5% of women who stopped screening said a doctor recommended it, while 48% said there was no recommendation. Among men who stopped PSA screening, only 3% said a doctor recommended stopping, and 54% said there was no recommendation. In other words, many older adults are not being guided out of low-value screening. They are drifting into it by habit.

Why the system keeps pushing older adults toward more care

This is where incentives and inertia matter. Screening is easy to order, easy to measure, and often easier to continue than to revisit. If no one raises the issue, the default is to keep going. For patients, stopping can feel like giving up. For clinicians, bringing up cessation can feel awkward, especially when the evidence is nuanced and the conversation takes time.

Older adults have said they want clearer communication about when to stop screening, and that need is practical, not abstract. The best conversations are direct: whether a patient is likely to live long enough to benefit, whether they would want follow-up treatment if cancer were found, and whether the burden of testing still matches their goals.

A simple way to frame the decision is this:

• If you are healthy and likely to live many more years, some screening may still be worthwhile.

• If your health is fragile, or if treatment would not be pursued even if cancer were found, screening is less likely to help.

• If your doctor never brings up stopping, ask whether the test still fits your age, health, and priorities.

Small changes in clinic systems can reduce unnecessary testing

One of the most encouraging findings comes from Northwestern Medicine, where electronic health record alerts were used to push clinicians away from low-value screening. After 18 months, unnecessary PSA screening fell by 9% and urine testing by 5.5% across 370 clinicians in 60 clinics.

That matters because it shows the problem is not only patient preference. It is also workflow. If a system reminds clinicians to order, it can also remind them not to order. Small design changes can reduce low-value care without waiting for every conversation to become perfect.

The broader lesson is that older-adult screening should not be treated as a reflex. As people age, the goal is not to do less medicine for its own sake. The goal is to do the right medicine, at the right time, for the right person. That means knowing which tests have crossed the line from helpful to unnecessary, and having the discipline to stop them when they no longer serve the patient.